Science Explorer Back to mapMap

Most cited papers from Elusys Therapeutics (United States)

What are the most cited papers from Elusys Therapeutics (United States)?

The most cited paper from Elusys Therapeutics (United States) is "A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore Challenge" (Nehal Mohamed, Michelle Clagett, Juan Li et al., 2005), with 124 citations. Next come "Enhancement of Anthrax Lethal Toxin Cytotoxicity: a Subset of Monoclonal Antibodies against Protective Antigen Increases Lethal Toxin-Mediated Killing of Murine Macrophages" (62) and "Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax" (49).

Showing 20 of 20 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore Challenge Nehal Mohamed, Michelle Clagett, Juan Li et al. · Infection and Immunity Open access 20 Jan 2005 124
2 Enhancement of Anthrax Lethal Toxin Cytotoxicity: a Subset of Monoclonal Antibodies against Protective Antigen Increases Lethal Toxin-Mediated Killing of Murine Macrophages Nehal Mohamed, Juan Li, Cláudia S. Ferreira et al. · Infection and Immunity Open access 20 May 2004 62
3 Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax Brent Yamamoto, Annette M. Shadiack, Sarah Carpenter et al. · Antimicrobial Agents and Chemotherapy Open access 19 Jul 2016 49
4 Inhaled vs subcutaneous effects of a dual IL‐4/IL‐13 antagonist in a monkey model of asthma Adrian Tomkinson, Jeffrey S. Tepper, Matthew T. Morton et al. · Allergy Oct 2009 46
5 Selective and efficient inhibition of the alternative pathway of complement by a mAb that recognizes C3b/iC3b David J. DiLillo, Andrew W. Pawluczkowycz, Peng Wu et al. · Molecular Immunology 15 Jun 2005 38
6 Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity Brent Yamamoto, Annette M. Shadiack, Sarah Carpenter et al. · Antimicrobial Agents and Chemotherapy Open access 19 Jul 2016 35
7 A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1) Alexander Repik, Steve E. Pincus, Ionita Calin Ghiran et al. · Clinical & Experimental Immunology Open access 11 Mar 2005 30
8 Animal‐to‐Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule CF Nagy, John T. Mondick, Natalya V. Serbina et al. · Clinical and Translational Science Open access 7 Dec 2016 25
9 Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans Christa F. Nagy, Timothy S. Leach, Alex King et al. · Clinical Pharmacology in Drug Development Open access 10 Nov 2017 22
10 Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies Christa F. Nagy, Timothy S. Leach, Joseph H. Hoffman et al. · Clinical Therapeutics Open access 30 Aug 2016 22
11 A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation Peng Wu, Xin Zhang, Nehal Mohamed et al. · Cancer Immunology Immunotherapy Open access 21 Apr 2005 20
12 Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen Lisa N. Henning, Sarah Carpenter, Gregory V. Stark et al. · Antimicrobial Agents and Chemotherapy Open access 13 Nov 2017 19
13 First clinical trials of a new heteropolymer technology agent in normal healthy volunteers and patients with systemic lupus erythematosus: safety and proof of principle of the antigen-heteropolymer ETI-104 Christof Iking‐Konert, Susan Jill Stocks, Frank Weinsberg et al. · Annals of the Rheumatic Diseases Open access 12 Aug 2004 18
14 Development and clinical validation of an automated cell cytotoxicity neutralization assay for detecting Clostridioides difficile toxins in clinically relevant stools samples Arik Elfassy, Warren V. Kalina, R. C. French et al. · Anaerobe 20 Jul 2021 12
15 Heteropolymers: a novel technology against blood-borne infections. Nehal Mohamed, Steven M Jones, Leslie S. Casey et al. · PubMed Apr 2005 12
16 Evaluation of Antigen-Based Heteropolymer for Treatment of Systemic Lupus Erythematosus in a Nonhuman Primate Model Steve E. Pincus · Clinical Immunology Nov 2002 8
17 Purification of antibody heteropolymers using hydrophobic interaction chromatography И. О. Костарева, Finn Hung, Colin William Barr Campbell · Journal of Chromatography A 6 Nov 2007 6
18 Treatment with an Anti-C3b/iC3b Monoclonal Antibody as an Adjuvant to Rituximab Enhances the Killing of Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Cells. Peng Wu, Xin Zhang, Juan Li et al. · Blood 16 Nov 2004 1
19 Therapeutic Potential of Cells of the Immune System Lawrence S. Lamb, William Ho · Elsevier eBooks Book chapter 2020 0
20 A novel dual antibody conjugate (Heteropolymer) reduces circulating HIV in a mouse model S. H. Pincus, SM Jones, TA Bradley et al. · Retrovirology Open access Dec 2006 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.